Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
BioLineRx (BLRX) PT Lowered to $2 at Maxim Group
-
Maxim Group Upgrades BioLineRx (BLRX) to Buy
-
BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
-
BioLineRx (BLRX) Prices 29.4M Offering at $0.85/ADS
-
BioLineRx Prices $25 Million Underwritten Public Offering
-
Maxim Group Downgrades BioLineRx (BLRX) to Hold
-
BioLineRx (BLRX) Bullish Stance Reiterated at Maxim Group After Entering Expansion stage of AML Phase 2 Study
-
BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
-
BioLineRx (BLRX) Prices 12.5M Public Offering at $2/ADS
-
BioLineRx Prices $25 Million Underwritten Public Offering of its American Depositary Shares
-
BioLineRx (BLRX) PT Raised to $8 at Maxim Group
-
Maxim Group Starts BioLineRx (BLRX) at Buy; Sees a Double
-
BioLineRx (BLRX) Closes 9.66M ADS Offering for Gross Proceeds of $24.1M
-
BioLineRx (BLRX) Prices 8.4M Offering at $2.50/ADS
-
BioLineRx (BLRX) Lower on Stock Offering

